Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.37 |
| ▸ | RHEB | Q15382 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522189 | 0.80 | SLC6A2 (0.46) | L3MBTL1TDP1NFE2L2HTR1ASLC6A2 | |
| SCHEMBL10035451 | 0.80 | L3MBTL1 (0.42) | L3MBTL1TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL14237478 | 0.77 | SLC6A2 (0.33) | HTR1ASLC6A2SLC6A3 | |
| SCHEMBL2784082 | 0.77 | ACHE (0.36) | L3MBTL1TDP1NFE2L2HTR1ASLC6A2 | |
| SCHEMBL14719203 | 0.77 | ALB (0.41) | L3MBTL1TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL333943 | 0.75 | CA3 (0.41) | NFE2L2ALDH1A1 | |
| SCHEMBL438800 | 0.75 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL30773497 | 0.75 | HTR1A (0.55) | L3MBTL1TDP1HTR1ASLC6A2ALDH1A1 | |
| SCHEMBL2389927 | 0.75 | HTR1A (0.55) | L3MBTL1TDP1HTR1ASLC6A2ALDH1A1 | |
| SCHEMBL931127 | 0.73 | KMT2A (0.41) | L3MBTL1TDP1NFE2L2SLC6A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 771 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109180499-B | Preparation method of rasagiline mesylate and intermediate thereof | 上海博志研新药物技术有限公司 | 2021-04-30 | — | — | CN | claimed |
| US-20260150574-A1 | COMPOSITION FOR ORGANIC OPTOELECTRONIC DIODE, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-20260124197-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-05-07 | — | — | US | disclosed |
| US-20260116891-A1 | Oxazepin Derivative | TEIJIN PHARMA LTD (JP) | 2026-04-30 | — | — | US | disclosed |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| US-12522582-B2 | Antiviral indolinyl compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4652154-A1 | NOVEL ALPK1 INHIBITORS | Pyrotech (Beijing) Biotechnology Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| EP-4637754-A2 | SELECTIVE BET INHIBITORS AND USES THEREOF | Tay Therapeutics Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| WO-2002083683-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002058695-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| EP-1216221-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6355648-B1 | COMPOUNDS AS CONTRACEPTIVES AND PROGESTERONE ANTAGONIST | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-12 | — | — | US | disclosed |
| EP-1144388-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001019770-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | L3MBTL1 1162/4885TDP1 46/4885NFE2L2 2151/4885 |
| US-20260124197-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YAP1, RCC1, YES1 | L3MBTL1 1800/4885TDP1 2595/4885NFE2L2 1527/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | L3MBTL1 3825/4885TDP1 3096/4885NFE2L2 3211/4885 |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | RIPK1, RIPK4, RIPK2 | L3MBTL1 1534/4885TDP1 1101/4885NFE2L2 3176/4885 |
| US-20260116891-A1 | Oxazepin Derivative | HCRTR2, HCRTR1, OXTR | L3MBTL1 3613/4885TDP1 4806/4885NFE2L2 1539/4885 |
| US-20260150574-A1 | COMPOSITION FOR ORGANIC OPTOELECTRONIC DIODE, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | OXER1, OR10J3, OPRD1 | L3MBTL1 394/4885TDP1 4700/4885NFE2L2 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.